Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany

Scholz S, Weidemann F, Damm O, Ultsch B, Greiner W, Wichmann O (2021)
Value in health 24(1): 32-40.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Scholz, Stefan ; Weidemann, Felix; Damm, Oliver; Ultsch, Bernhard; Greiner, WolfgangUniBi; Wichmann, Ole
Abstract / Bemerkung
OBJECTIVES: In Germany, routine influenza vaccination with quadrivalent influenza vaccines (QIV) is recommended and reimbursed for individuals ≥60 years of age and individuals with underlying chronic conditions. The present study examines the cost-effectiveness of a possible extension of the recommendation to include strategies of childhood vaccination against seasonal influenza using QIV.; METHODS: A dynamic transmission model was used to examine the epidemiological impact of different childhood vaccination strategies. The outputs were used in a health economic decision tree to calculate the costs per quality-adjusted life year (QALY) gained from a societal and a third-party payer (TPP) perspective. Strain-specific epidemiology, vaccine uptake, and vaccine efficacy data from the 10 non-pandemic seasons from 2003/2004 to 2013/2014 were used, and cost data were drawn mainly from a health insurance claims data analysis and supplemented by estimates from literature. Uncertainty is explored via scenario, deterministic, and probabilistic sensitivity analyses.; RESULTS: Vaccinating 2- to 9-year-olds with QIV assuming a vaccine uptake of 40% is cost-saving with a benefit-cost ratio of 1.66 from a societal perspective and an incremental cost-effectiveness ratio of 998/QALY from a TPP perspective. Lower and higher vaccine uptakes show marginal effects, while extending the target group to 2- to 17-year-olds further increases the health benefits while still being below the willingness-to-pay (WTP) threshold. Assuming no vaccine-induced herd protection has a negative effect on the cost-effectiveness ratio, but childhood vaccination remains cost-effective.; CONCLUSION: Routine childhood vaccination against seasonal influenza in Germany is most likely to be cost-saving from a societal perspective and highly cost-effective from a TPP perspective. Copyright © 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.
Erscheinungsjahr
2021
Zeitschriftentitel
Value in health
Band
24
Ausgabe
1
Seite(n)
32-40
eISSN
1524-4733
Page URI
https://pub.uni-bielefeld.de/record/2950419

Zitieren

Scholz S, Weidemann F, Damm O, Ultsch B, Greiner W, Wichmann O. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value in health. 2021;24(1):32-40.
Scholz, S., Weidemann, F., Damm, O., Ultsch, B., Greiner, W., & Wichmann, O. (2021). Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value in health, 24(1), 32-40. https://doi.org/10.1016/j.jval.2020.05.022
Scholz, S., Weidemann, F., Damm, O., Ultsch, B., Greiner, W., and Wichmann, O. (2021). Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value in health 24, 32-40.
Scholz, S., et al., 2021. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value in health, 24(1), p 32-40.
S. Scholz, et al., “Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany”, Value in health, vol. 24, 2021, pp. 32-40.
Scholz, S., Weidemann, F., Damm, O., Ultsch, B., Greiner, W., Wichmann, O.: Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value in health. 24, 32-40 (2021).
Scholz, Stefan, Weidemann, Felix, Damm, Oliver, Ultsch, Bernhard, Greiner, Wolfgang, and Wichmann, Ole. “Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany”. Value in health 24.1 (2021): 32-40.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 33431151
PubMed | Europe PMC

Suchen in

Google Scholar